Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545762 · ClinicalTrials.gov registry record · Phase 1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by C. Babis Andreadis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04545762 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by C. Babis Andreadis. The registered enrollment target is 36 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04545762, a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by C. Babis Andreadis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL anti-CD19 CAR-T cells
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545762
The ClinicalTrials.gov registry entry for NCT04545762 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is C. Babis Andreadis, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04545762 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04545762 about?
NCT04545762 is a clinical study titled "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma". This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
What is the current status of trial NCT04545762?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-09-11. Estimated completion is 2026-10-31.
What conditions does trial NCT04545762 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT04545762?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), anti-CD19 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04545762?
This trial is sponsored by C. Babis Andreadis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04545762 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.